S&P 500   3,344.91 (-0.20%)
DOW   27,499.82 (-0.31%)
QQQ   277.19 (+0.00%)
AAPL   114.50 (-0.40%)
MSFT   208.83 (-0.29%)
FB   259.31 (+0.97%)
GOOGL   1,465.49 (+0.47%)
AMZN   3,170.00 (-0.13%)
TSLA   416.61 (-1.09%)
NVDA   525.07 (+0.70%)
BABA   278.75 (+0.99%)
CGC   14.42 (+1.48%)
MU   50.87 (+2.31%)
GE   6.15 (-0.81%)
AMD   81.00 (+1.91%)
T   28.40 (+0.07%)
F   6.66 (-0.45%)
ACB   4.63 (-3.14%)
GILD   62.48 (-0.59%)
NFLX   489.70 (-0.19%)
DIS   124.71 (-1.02%)
BA   163.44 (-1.59%)
BAC   23.95 (-0.58%)
S&P 500   3,344.91 (-0.20%)
DOW   27,499.82 (-0.31%)
QQQ   277.19 (+0.00%)
AAPL   114.50 (-0.40%)
MSFT   208.83 (-0.29%)
FB   259.31 (+0.97%)
GOOGL   1,465.49 (+0.47%)
AMZN   3,170.00 (-0.13%)
TSLA   416.61 (-1.09%)
NVDA   525.07 (+0.70%)
BABA   278.75 (+0.99%)
CGC   14.42 (+1.48%)
MU   50.87 (+2.31%)
GE   6.15 (-0.81%)
AMD   81.00 (+1.91%)
T   28.40 (+0.07%)
F   6.66 (-0.45%)
ACB   4.63 (-3.14%)
GILD   62.48 (-0.59%)
NFLX   489.70 (-0.19%)
DIS   124.71 (-1.02%)
BA   163.44 (-1.59%)
BAC   23.95 (-0.58%)
S&P 500   3,344.91 (-0.20%)
DOW   27,499.82 (-0.31%)
QQQ   277.19 (+0.00%)
AAPL   114.50 (-0.40%)
MSFT   208.83 (-0.29%)
FB   259.31 (+0.97%)
GOOGL   1,465.49 (+0.47%)
AMZN   3,170.00 (-0.13%)
TSLA   416.61 (-1.09%)
NVDA   525.07 (+0.70%)
BABA   278.75 (+0.99%)
CGC   14.42 (+1.48%)
MU   50.87 (+2.31%)
GE   6.15 (-0.81%)
AMD   81.00 (+1.91%)
T   28.40 (+0.07%)
F   6.66 (-0.45%)
ACB   4.63 (-3.14%)
GILD   62.48 (-0.59%)
NFLX   489.70 (-0.19%)
DIS   124.71 (-1.02%)
BA   163.44 (-1.59%)
BAC   23.95 (-0.58%)
S&P 500   3,344.91 (-0.20%)
DOW   27,499.82 (-0.31%)
QQQ   277.19 (+0.00%)
AAPL   114.50 (-0.40%)
MSFT   208.83 (-0.29%)
FB   259.31 (+0.97%)
GOOGL   1,465.49 (+0.47%)
AMZN   3,170.00 (-0.13%)
TSLA   416.61 (-1.09%)
NVDA   525.07 (+0.70%)
BABA   278.75 (+0.99%)
CGC   14.42 (+1.48%)
MU   50.87 (+2.31%)
GE   6.15 (-0.81%)
AMD   81.00 (+1.91%)
T   28.40 (+0.07%)
F   6.66 (-0.45%)
ACB   4.63 (-3.14%)
GILD   62.48 (-0.59%)
NFLX   489.70 (-0.19%)
DIS   124.71 (-1.02%)
BA   163.44 (-1.59%)
BAC   23.95 (-0.58%)
Log in
NASDAQ:PRTA

Prothena Stock Forecast, Price & News

$9.84
-0.16 (-1.60 %)
(As of 09/29/2020 10:28 AM ET)
Add
Compare
Today's Range
$9.84
Now: $9.84
$10.04
50-Day Range
$10.02
MA: $12.13
$13.35
52-Week Range
$7.10
Now: $9.84
$17.63
Volume254 shs
Average Volume258,903 shs
Market Capitalization$392.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Read More
Prothena logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRTA
CUSIPN/A
Phone011-353-1236-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$810,000.00
Book Value$6.84 per share

Profitability

Net Income$-77,680,000.00
Net Margins-11,399.37%

Miscellaneous

Employees59
Market Cap$392.72 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$9.84
-0.16 (-1.60 %)
(As of 09/29/2020 10:28 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Prothena (NASDAQ:PRTA) Frequently Asked Questions

How has Prothena's stock price been impacted by COVID-19 (Coronavirus)?

Prothena's stock was trading at $9.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRTA stock has increased by 2.5% and is now trading at $9.96.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Prothena?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Prothena
.

When is Prothena's next earnings date?

Prothena is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Prothena
.

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) posted its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.02. The biotechnology company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.18 million. Prothena had a negative return on equity of 34.56% and a negative net margin of 11,399.37%.
View Prothena's earnings history
.

What price target have analysts set for PRTA?

4 brokerages have issued 1-year target prices for Prothena's shares. Their forecasts range from $14.00 to $19.00. On average, they anticipate Prothena's share price to reach $17.50 in the next year. This suggests a possible upside of 75.7% from the stock's current price.
View analysts' price targets for Prothena
.

Are investors shorting Prothena?

Prothena saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 1,530,000 shares, an increase of 15.9% from the July 30th total of 1,320,000 shares. Based on an average trading volume of 289,200 shares, the short-interest ratio is presently 5.3 days.
View Prothena's Short Interest
.

Who are some of Prothena's key competitors?

What other stocks do shareholders of Prothena own?

Who are Prothena's key executives?

Prothena's management team includes the following people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)
  • Mr. Tran B. Nguyen, CFO & COO (Age 45)
  • Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)
  • Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 46)

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $9.96.

How big of a company is Prothena?

Prothena has a market capitalization of $397.51 million and generates $810,000.00 in revenue each year. The biotechnology company earns $-77,680,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Prothena employs 59 workers across the globe.

What is Prothena's official website?

The official website for Prothena is www.prothena.com.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.